Insight

Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events

Carmine Valenza/X

Dec 5, 2024, 07:25

Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on X:

“Happy to share our last paper on the role of germline BRCA mutation in PARP inhibitors-related hematologic adverse events.

No differences between carriers vs. non-carriers.

Thanks to all the coauthors, Eleonora Nicolò, Dario Trapani, Luca Boscolo Bielo, Lorenzo Guidi, G Curigliano.”

Title: Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study

Authors: Carmine Valenza, Eleonora Nicolò, Marta Mongillo, Dario Trapani, Jalissa Katrini, Laura Boldrini, Luca Boscolo Bielo, Grazia Castellano, Lorenzo Guidi, Gloria Pellizzari, Jacopo Villa, Silvia Derio, Mariateresa Lapresa, Federica Gigli, Gabriella Parma, Emanuela Omodeo Salè, Enrico Derenzini, Giuseppe Curigliano and Nicoletta Colombo

Carmine Valenza

More posts featuring Carmine Valenza.

BRCA mutation cancer Carmine Valenza Dario Trapani Eleonora Nicolò Emanuela Omodeo Salè Enrico Derenzini germline Giuseppe Curigliano Gloria Pellizzari Grazia Castellano hematologic adverse events IEO Jacopo Villa Jalissa Katrini Laura Boldrini Lorenzo Guidi Luca Boscolo Bielo Mariateresa Lapresa Marta Mongillo Nicoletta Colombo OncoDaily Oncology PARP inhibitors Silvia Derio

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

New FDA PreCheck Program to Boost U.S. Drug Manufacturing

Vinay Prasad Rejoins FDA Days After Exit